CEL-SCI (CVM) Competitors $2.25 -0.12 (-5.06%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.24 -0.02 (-0.67%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. ALXO, BCAB, ALLK, FGEN, ONCY, VOR, FBLG, INKT, GRCE, and PASGShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include ALX Oncology (ALXO), BioAtla (BCAB), Allakos (ALLK), FibroGen (FGEN), Oncolytics Biotech (ONCY), Vor Biopharma (VOR), FibroBiologics (FBLG), MiNK Therapeutics (INKT), Grace Therapeutics (GRCE), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors ALX Oncology BioAtla Allakos FibroGen Oncolytics Biotech Vor Biopharma FibroBiologics MiNK Therapeutics Grace Therapeutics Passage Bio CEL-SCI (NYSE:CVM) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Which has more risk & volatility, CVM or ALXO? CEL-SCI has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Does the MarketBeat Community prefer CVM or ALXO? ALX Oncology received 57 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 64.04% of users gave ALX Oncology an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes27100.00% ALX OncologyOutperform Votes5764.04% Underperform Votes3235.96% Which has stronger earnings & valuation, CVM or ALXO? ALX Oncology is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$12.61-0.18ALX OncologyN/AN/A-$160.80M-$2.47-0.21 Do analysts rate CVM or ALXO? ALX Oncology has a consensus target price of $3.30, indicating a potential upside of 544.03%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is CVM or ALXO more profitable? ALX Oncology's return on equity of -93.02% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% ALX Oncology N/A -93.02%-70.67% Does the media refer more to CVM or ALXO? In the previous week, ALX Oncology had 5 more articles in the media than CEL-SCI. MarketBeat recorded 5 mentions for ALX Oncology and 0 mentions for CEL-SCI. ALX Oncology's average media sentiment score of 0.97 beat CEL-SCI's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media. Company Overall Sentiment CEL-SCI Neutral ALX Oncology Positive Do institutionals & insiders hold more shares of CVM or ALXO? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 9.9% of CEL-SCI shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryALX Oncology beats CEL-SCI on 14 of the 15 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$7.19M$3.09B$5.57B$19.68BDividend YieldN/A1.56%5.27%3.81%P/E Ratio-4.6932.6326.7834.98Price / SalesN/A455.18404.4942.86Price / CashN/A168.6838.2517.51Price / Book15.003.366.964.78Net Income-$26.92M-$72.35M$3.23B$1.02B7 Day Performance-5.46%0.36%-1.24%0.82%1 Month Performance-68.91%16.48%8.34%1.74%1 Year Performance-94.23%-15.35%33.30%10.57% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI0.0781 of 5 stars$2.25-5.1%N/A-94.2%$7.19MN/A-4.6943High Trading VolumeALXOALX Oncology2.6778 of 5 stars$0.56+15.1%$3.30+490.7%-93.9%$29.83MN/A-0.1940Analyst RevisionGap UpBCABBioAtla2.7957 of 5 stars$0.51+24.7%$5.00+880.4%-74.2%$29.79M$11M-0.3060High Trading VolumeALLKAllakos4.3008 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190FGENFibroGen4.5424 of 5 stars$0.29+2.2%$10.00+3,303.7%-77.3%$29.69M$7.00M-0.24570News CoverageStock SplitGap DownONCYOncolytics Biotech1.463 of 5 stars$0.34+1.2%$4.33+1,159.7%-41.0%$29.44MN/A-1.2730VORVor Biopharma2.7878 of 5 stars$0.23+17.2%$7.06+2,912.0%-84.8%$29.28MN/A-0.14140News CoverageShort Interest ↑Gap DownHigh Trading VolumeFBLGFibroBiologics3.2487 of 5 stars$0.76+4.6%$13.00+1,603.6%-88.7%$29.20MN/A-3.6310INKTMiNK Therapeutics3.1106 of 5 stars$7.18+2.1%$37.50+422.6%-24.3%$28.60MN/A-1.8430Short Interest ↓Gap DownGRCEGrace Therapeutics2.5076 of 5 stars$2.81+1.4%$12.00+327.0%N/A$28.49MN/A-2.42N/ANews CoverageUpcoming EarningsPASGPassage Bio2.7597 of 5 stars$0.440.0%$7.50+1,619.4%-63.5%$27.11MN/A-0.37130Positive News Related Companies and Tools Related Companies ALX Oncology Competitors BioAtla Competitors Allakos Competitors FibroGen Competitors Oncolytics Biotech Competitors Vor Biopharma Competitors FibroBiologics Competitors MiNK Therapeutics Competitors Grace Therapeutics Competitors Passage Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
